Cyclic vinylogous amides as bromodomain inhibitors

A method for treating a disease or disorder arising from inappropriate activity of proteins containing an acetyl-lysine residue, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I

• wherein:
• U is (CH2)n, where n=1, 2 or 3;
• R1 is selected from the group consisting of:
• (C1-C10)alkyl, substituted (C1-C10)alkyl, and nitrile;
• Cy is a carbocycle or heterocycle;
• R11 and R12 are independently selected from the group consisting of:
• H, (C1-C10)alkyl, (C1-C10)perfluoroalkyl, halogen, nitrile, hydroxy, (C1-C10)alkoxy, perfluoro(C1-C10)alkoxy, (C1-C10)alkylthio, amino, (C1-C10)alkylamino, (C1-C10)acylamino, aryl, heteroaryl, aminocarbonyl, carboxyl, and (C1-C10)alkoxycarbonyl;
• or
• taken together, R11 and R12 may form a 5, 6, or 7-membered carbocycle or heterocycle wherein said carbocycle or heterocycle may be optionally substituted with R2;
• R2 is selected from the group consisting of:
• halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy, (C1-C4)alkoxy, halo(C1-C4)alkoxy, carboxy, amino, (C1-C4)alkylamino and di(C1-C4)alkylamino;
• Y is selected from,
• L and L′ are independently a bond or (CR3R4)m where R3 and R4 are independently selected from the group consisting of H and (C1-C4)alkyl, and m is 1 or 2;
• R10 is chosen from alkyl, carbocycle and heterocycle, wherein said alkyl, carbocycle or heterocycle is optionally substituted with R7 and/or R8;
• R20 is —C(═O)OR21;
• R21 is chosen from H and (C1-C4)alkyl;
• R5 and R6 are independently selected from the group consisting of hydrogen, hydroxy, (C1-C10) hydrocarbyl, halo(C1-C10)hydrocarbyl, and (C1-C10)alkoxy;
• R7 and R8 are independently selected from the group consisting of:
• hydroxy, halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkylthio, (C1-C4)alkylcarbonyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cyano, oxo, (C1-C4)alkylsulfonyl, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, (C1-C4)acylamino, aminocarbonyl, carboxyl, and (C1-C4)alkoxycarbonyl, where each said alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, may be further optionally substituted with hydroxy, oxo, carboxy, carboxy(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl, (C1-C4)alkoxycarbonyl(C1-C4)alkyl, amino, (C1-C4)alkylamino, di (C1-C4)alkylamino, amido, (C1-C4)alkylamido, di (C1-C4)alkylamido, halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, aryl, heteroaryl, heterocycloalkyl, or cycloalkyl;
• or, taken together, R5 and R6, or R7 and R8 may form a 5, 6, or 7-membered carbocycle or heterocycle, wherein said carbocycle or heterocycle is optionally substituted with R9;
• R9 is selected from the group consisting of:
• halogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino and di(C1-C4)alkylamino.